To further determine whether the beneficial effect of SIRT2 inhibition in the AD mouse model is RTN4B‐dependent, we knocked down the RTN4B and then examined whether the effect of SIRT2 inhibition is still effective in vivo (Figure 5a). The gene discussed is SIRT2; the disease is Alzheimer disease.